Targeting Unmet Patient Needs in Diffuse Large B-Cell Lymphoma (DLBCL) Emerging Strategies for the Interprofessional Healthcare Team
This Grand Rounds educational series is targeted to hematologists, hematologist-oncologists, community oncologists, pharmacists, nurses, nurse practitioners, and other members of the healthcare team who treat patients with diffuse large B-cell lymphoma (DLBCL).
- Review failure rates associated with the use of R-CHOP for diffuse large B-cell lymphoma (DLBCL) and the factors that contribute to increased risk of disease progression or relapse.
- Examine the health system costs associated with treating relapsed or refractory DLBCL, highlighting the need for better front-line therapies for these patients.
- Explore key clinical pearls and differentiating factors between novel, alternative and emerging front-line therapy options for DLBCL and their potential for improving patient outcomes, specifically in the front-line treatment setting.
Supported through an independent educational grant from Genentech.
Presented by Creative Educational Concepts, LLC.
Loretta J. Nastoupil, MD
Director, Lymphoma Outcomes Database
Section Chief, New Drug Development and Indolent Lymphoma
Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Amy L. Goodrich, RN, MSN, CRNP-AC-has disclosed that she is a consultant for Abbvie, AstraZeneca, BeiGene, Epizyme, Genentech, Pharmacyclics, Sanofi, and Seagen.
Elizabeth A. Travers, PharmD, BCOP–has no relevant financial relationships to disclose in relation to the content of this activity.
John Allan, MD–has disclosed that he is a consultant for Abbvie, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, and PCYC; receives grant/research support from BeiGene, Celgene, Genentech, Janssen, and TG Therapeutics. He is also a member of the speakers’ bureau for Abbvie, BeiGene, and PCYC/Janssen.
Loretta J. Nastoupil, MD–has disclosed that she is a consultant for ADC therapeutics, Bayer, BMS/Celgene, Genentech, Epizyme, Janssen, Gilead, Morphosys and Novartis. She receives grant/research support from BMS/Celgene, Genentech, Epizyme, Gilead, Genentech, Novartis, Janssen, Pfizer and TG Therapeutics.
Jeanie Patrick, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Lisa Shotyk, RN, MSN, APN-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Tina L. Trieu, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-001-L01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 ICPE
- 1.00 Participation